Can a Low-Dose cancer drug stop liver cancer before it starts?
NCT ID NCT04172779
Summary
This study is testing whether a low dose of the cancer drug erlotinib can prevent liver cancer from developing in people who have advanced liver scarring (cirrhosis). Sixty participants will be randomly assigned to receive either the drug or a placebo for one year. Researchers will track changes in blood markers linked to cancer risk and monitor side effects to see if this approach is safe and effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS, LIVER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.